IVVD — Invivyd, Inc.
$0.6134+0.54%
Last close: · regular session
Last 60 sessions
Opening the full analysis uses 1 of your 3 free tickers today.
Chart, dilution, float and news for IVVD in the TickerWise workspace.
Adagio Therapeutics, Inc., a biopharmaceutical firm in its clinical development phase, operates within the United States, specializing in the discovery, progression, and marketing of antibody-derived solutions for infectious diseases. The company's leading drug candidate, ADG20 (adintrevimab), is a neutralizing antibody currently undergoing Phase 3 clinical investigation for both the management and prevention of coronavirus disease. Adagio Therapeutics maintains collaborative agreements with Adimab, LLC to facilitate the identification and enhancement of its exclusive antibodies. Furthermore, it partners with the Scripps Research Institute to conduct studies aimed at uncovering potential vaccine solutions for the prophylaxis, detection, or therapy of influenza or beta coronaviruses. Incorporated in 2020, the company's base of operations is in Waltham, Massachusetts.
Company profile
- Sector: Healthcare
- Industry: Biotechnology
- Country: US
- Exchange: NASDAQ Global Market
- Employees: 99
- Website: https://www.invivyd.com
Latest SEC filings for IVVD
Latest IVVD news
- Invivyd and the SPEAR Study Group Announce Initiation of “FLINTLOCK” Phase 2 Study of VYD2311, a Monoclonal Antibody for the Potential Treatment of Long COVID or Post-Vaccination Syndrome Read article
- Invivyd’s VYD2311 Phase III Study Meets Safety Goals, Eyes FDA Accelerated Approval Read article
- Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Read article
- Invivyd drops after delaying late-stage trial data for COVID therapy Read article
- Invivyd Outlines Accelerated Approval Submission Path with FDA for COVID-19 Antibody Read article
- Invivyd, Inc. (IVVD) Discusses LIBERTY Phase III Topline Data and Next Steps for VYD2311 Regulatory Submission Transcript Read article
- In a trial, 56.5% had an adverse event, injection reaction or allergy with Invivyd's COVID antibody, versus 91.4% with an mRNA vaccine.
- Invivyd Announces Positive Topline Results from LIBERTY Phase 3 Study Demonstrating VYD2311 Safety and Tolerability Superior to mRNA-based COVID-19 Vaccine; Announces Regulatory Submission Plans for VYD2311 Read article
Opening the full analysis uses 1 of your 3 free tickers today.
Educational tool only — not investment advice.